<DOC>
	<DOCNO>NCT01019369</DOCNO>
	<brief_summary>Depot medroxyprogesterone acetate ( DepoProvera ) acceptable form contraception many woman . However , difficulty access may cause many woman discontinue use , often without use another effective method contraception , thereby leave vulnerable unintended pregnancy . This study randomly assign woman present contraceptive service two group : self clinic administer SC DMPA . The participant follow one year compare continuation rate , acceptability , cost effectiveness , evidence skin change , need continue support two group .</brief_summary>
	<brief_title>Study Self Clinic Administration DepoProvera</brief_title>
	<detailed_description>Unintended pregnancy remain worldwide problem develop develop country . In 2001 , 49 % pregnancy United States unintended . Moreover , 6 million woman annually high risk become unintentionally pregnant gap contraceptive use , disadvantage woman likely difficulty others continuous method use . Multiple strategy explore implemented increase effective usage contraception , include promote use longer act reversible contraceptive . Difficulty access depot medroxyprogesterone acetate ( DMPA ) remain problem . With advent subcutaneous formulation DMPA , administration outside clinical set possible . The acceptability self administer DMPA also review , favorable outcomesÍ¾ however , actual intervention study . This study recruit woman present abortion contraceptive service Columbia University New York Presbyterian affiliate Family Planning Clinic Special Gynecology Services desire DMPA contraception . Women randomize two group : self administration SC DMPA clinic administration SC DMPA . The primary objective study compare continuation rate SC DMPA self clinic administration group 6 month . Secondary outcome include participant satisfaction , cost effectiveness self-injected use DMPA , baseline predictor method continuation discontinuation , evidence persistent skin change follow administration SC DMPA , need continued clinical support .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>1. age great equal 18 year 2. seek DMPA contraception 3 . English Spanish speak 4. consistent access work telephone 5. availability follow one year 1. suspect continue pregnancy 2. undiagnosed vaginal bleeding 3. know suspect breast cancer 4. acute liver disease 5. know hypersensitivity medroxyprogesterone acetate component DMPA 6. desire pregnancy within one year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Medroxyprogesterone 17-acetate</keyword>
	<keyword>Self administration</keyword>
</DOC>